



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Yunsheng Liang
✉ yunshengliang@aliyun.com
Suyun Ji
✉ gddhjisuyun@smu.edu.cn

†These authors have contributed
equally to this work and share first
authorship

SPECIALTY SECTION
This article was submitted to
Dermatology,
a section of the journal
Frontiers in Medicine

RECEIVED 16 December 2022
ACCEPTED 20 December 2022
PUBLISHED 05 January 2023

CITATION
Hou Z, Su X, Han G, Xue R, Chen Y,
Chen Y, Wang H, Yang B, Liang Y and
Ji S (2023) Corrigendum: JAK1/2
inhibitor baricitinib improves skin
fibrosis and digital ulcers in systemic
sclerosis. *Front. Med.* 9:1125836.
doi: 10.3389/fmed.2022.1125836

COPYRIGHT
© 2023 Hou, Su, Han, Xue, Chen,
Chen, Wang, Yang, Liang and Ji. This is
an open-access article distributed
under the terms of the [Creative
Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction
in other forums is permitted, provided
the original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.

Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis

Zhanying Hou^{1,2†}, Xuehan Su^{3,1†}, Guangming Han^{4†},
Ruzeng Xue¹, Yangxia Chen¹, Ye Chen¹, Huan Wang¹,
Bin Yang¹, Yunsheng Liang^{1*} and Suyun Ji^{1*}

¹Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China, ²Department of Dermatology, Shenzhen Longhua District Central Hospital, Shenzhen, China, ³The First School of Clinical Medicine, Southern Medical University, Guangzhou, China, ⁴Department of Rheumatology, Dermatology Hospital, Southern Medical University, Guangzhou, China

KEYWORDS

baricitinib, JAK inhibitor, systemic sclerosis, skin fibrosis, digital ulcers

A corrigendum on JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis

by Hou, Z., Su, X., Han, G., Xue, R., Chen, Y., Chen, Y., Wang, H., Yang, B., Liang, Y., and Ji, S. (2022). *Front. Med.* 9:859330. doi: 10.3389/fmed.2022.859330

In the published article, there was an error regarding the affiliations for author “Xuehan Su.” As well as having the affiliation “Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China,” they should also have “The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.